Our Story

Since 2002, Lilly Ventures has
focused its investments in
great companies with
compelling life science
innovations that have the
potential to create a
pipeline of life-changing
medicines. We partner actively
with our portfolio company
management teams and
provide intellectual, as
well as financial, resources
to accelerate the path to
success.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
July 19, 2018

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

view full story

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
July 16, 2018

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

view full story

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
July 9, 2018

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology

view full story

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
June 18, 2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

view full story

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
June 12, 2018

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

view full story

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
June 5, 2018

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts

view full story

Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
May 24, 2018

Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer

view full story

Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
May 16, 2018

Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors

view full story

Aileron Therapeutics Announces Changes to Management
May 15, 2018

Aileron Therapeutics Announces Changes to Management

view full story

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment
April 26, 2018

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment

view full story

Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors
April 23, 2018

Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors

view full story

Surface Oncology Announces $119.5 Million Aggregate Financing
April 18, 2018

Surface Oncology Announces $119.5 Million Aggregate Financing

view full story

Aeglea BioTherapuetics: New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients
April 12, 2018

Aeglea BioTherapuetics:  New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients

view full story

Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors
April 9, 2018

Tim Clackson, Ph.D., Named to FORMA Therapeutics Board of Directors

view full story

FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program
April 5, 2018

FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program

view full story

Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality
April 4, 2018

Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality

view full story

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease
April 2, 2018

Symic Bio Announces 12-Month Results from the SHIELD Trial of SB-030 in Peripheral Vascular Disease

view full story

Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials
April 2, 2018

Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials

view full story

Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
March 20, 2018

Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231

view full story

First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy
March 20, 2018

First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy

view full story

Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
March 19, 2018

Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors

view full story

Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
March 8, 2018

Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase

view full story

InCube Portfolio Company Rani Therapeutics Funding Robotic Pill
February 9, 2018

InCube Portfolio Company Rani Therapeutics Funding Robotic Pill

view full story

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
February 7, 2018

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

view full story